NCT06617416 2025-03-12
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Akeso
Phase 3 Recruiting
Clinical Trials
3 trialsNCT05131438 2023-03-27
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
EQRx International, Inc.
No longer available
NCT04194801 2023-02-06
A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma
CStone Pharmaceuticals
Phase 1/2 Completed